|
시장보고서
상품코드
1762250
세계의 연부육종 치료 시장 : 시장 규모, 점유율 및 동향, 업계 분석(치료법별, 적응증별, 유통 채널별, 최종 용도별, 지역별), 예측(2025-2034년)Soft Tissue Sarcoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, Indication, Distribution Channel, End Use, and Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, 연부육종 치료제 시장 규모는 2034년까지 39억 1,015만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
연부육종 치료 시장은 근육, 지방, 혈관, 신경, 결합조직에 영향을 미치는 희귀암 그룹인 연부육종을 관리하는 데 사용되는 치료에 초점을 맞추었습니다. 암 발병률 증가, 표적치료제 및 면역치료의 발전, 연구개발 활동의 활성화가 연부육종 치료제 시장의 성장을 견인하고 있습니다. 규제 당국의 승인과 임상시험의 확대는 새로운 치료 옵션의 도입을 촉진하고 환자 결과를 개선하고 있습니다. 정밀의료, 인공지능 기반 진단, 신흥 시장에서의 치료 접근성 확대 등이 치료 기회로 작용하고 있습니다. 병용요법, 전략적 제휴, 외래 치료 모델과 같은 추세는 전체 시장 확대에 더욱 기여하고 있습니다.
연부육종 치료제 시장 : 분석 개요
표적치료제는 기존 화학요법 대비 효능이 향상되고 부작용이 감소하여 연부육종 치료제 시장에서 가장 큰 비중을 차지하고 있습니다. 혈관 신생 억제제는 현재 진행 중인 연구와 규제 당국의 승인 증가로 인해 가장 빠르게 성장하고 있습니다.
국소 연부육종은 조기에 진단되는 경우가 많고, 수술과 방사선 치료가 효과적이기 때문에 적응증별 시장 점유율이 가장 큰 시장입니다. 전이성 육종(metastatic sarcoma)은 환자 수 증가와 고급 치료 옵션에 대한 수요로 인해 가장 빠르게 성장하고 있는 분야입니다.
유통 채널별로는 디지털화의 진전과 택배 서비스의 편리성으로 인해 온라인 약국의 성장률이 가장 높은 것으로 나타났습니다.
최종 용도별로는 종합적인 암 치료를 제공하는 1차 치료 센터 역할을 하는 병원 분야가 가장 큰 비중을 차지하고 있습니다. 재택 치료는 재택 치료 옵션에 대한 선호도 증가와 약물 전달 방법의 발전으로 가장 빠르게 성장하고 있는 분야입니다.
북미는 높은 의료비, 첨단 치료법, 강력한 규제 지원으로 인해 연부육종 치료 시장 점유율을 독식하고 있습니다. 아시아태평양은 가장 빠르게 성장하는 시장으로, 의료 인프라 개선, 인지도 향상, 첨단 치료법 채택 증가 등이 그 요인으로 작용하고 있습니다.
주요 시장 기업으로는 Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Johnson & Johnson Services, Inc. Johnson &Johnson Services, Inc.,Merck &Co.,Novartis AG,Pfizer Inc.,Sanofi 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 분석 방법
제4장 세계의 연부육종 치료 시장 인사이트
- 시장 현황
- 연부육종 치료 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTLE 분석
- 연부육종 치료 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 연부육종 치료 시장 : 치료법별
- 주요 분석 결과
- 서론
- 화학요법
- 표적치료
- 혈관신생 억제제
- 방사선 치료
제6장 세계의 연부육종 치료 시장 : 적응증별
- 주요 분석 결과
- 서론
- 국부
- 국소성
- 전이성 육종
제7장 세계의 연부육종 치료 시장 : 최종 용도별
- 주요 분석 결과
- 서론
- 병원
- 재택치료
- 기타
제8장 세계의 연부육종 치료 시장 : 유통 채널별
- 주요 분석 결과
- 서론
- 온라인 약국
- 소매 약국
- 기타
제9장 세계의 연부육종 치료 시장 : 지역별
- 주요 분석 결과
- 서론
- 연부육종 치료 시장 분석 : 지역별(2020-2034년)
- 북미
- 북미 : 치료법별(2020-2034년)
- 북미 : 적응증별(2020-2034년)
- 북미 : 최종 용도별(2020-2034년)
- 북미 : 유통 채널별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 치료법별(2020-2034년)
- 유럽 : 적응증별(2020-2034년)
- 유럽 : 최종 용도별(2020-2034년)
- 유럽 : 유통 채널별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 치료법별(2020-2034년)
- 아시아태평양 : 적응증별(2020-2034년)
- 아시아태평양 : 최종 용도별(2020-2034년)
- 아시아태평양 : 유통 채널별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 치료법별(2020-2034년)
- 중동 및 아프리카 : 적응증별(2020-2034년)
- 중동 및 아프리카 : 최종 용도별(2020-2034년)
- 중동 및 아프리카 : 유통 채널별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 치료법별, 2020-2034년
- 라틴아메리카 : 적응증별(2020-2034년)
- 라틴아메리카 : 최종 용도별(2020-2034년)
- 라틴아메리카 : 유통 채널별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 사업 확대 및 기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
The soft tissue sarcoma treatment market size is expected to reach USD 3,910.15 million by 2034, according to a new study by Polaris Market Research. The report "Soft Tissue Sarcoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Targeted Therapy, Anti-angiogenesis Drugs, and Radiation Therapy), Indication, Distribution Channel, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The soft tissue sarcoma treatment market focuses on therapies used to manage soft tissue sarcomas, a group of rare cancers affecting muscles, fat, blood vessels, nerves, and connective tissues. The increasing incidence rates of cancer, advancements in targeted therapy and immunotherapy, and rising research and development activities propel the soft tissue sarcoma treatment market growth. Regulatory approvals and expanding clinical trials are driving the introduction of novel treatment options, improving patient outcomes. Opportunities lie in precision medicine, artificial intelligence-based diagnostics, and the expansion of treatment accessibility in emerging markets. Trends such as combination therapies, strategic collaborations, and outpatient treatment models are further contributing to the overall market expansion.
Soft Tissue Sarcoma Treatment Market Report Highlights
Based on treatment, the targeted therapy segment holds the largest share of the soft tissue sarcoma treatment market revenue due to its improved efficacy and reduced side effects compared to traditional chemotherapy. Anti-angiogenesis drugs are witnessing the fastest growth, driven by ongoing research and increasing regulatory approvals.
The localized soft tissue sarcoma segment, by indication, accounts for the largest market share as it is often diagnosed early and treated effectively with surgery and radiation. Metastatic sarcoma is the fastest-growing segment due to increasing cases and the demand for advanced treatment options.
Based on distribution channel, the online pharmacies segment is growing at the highest rate due to increasing digitalization and the convenience of home delivery services.
The hospitals segment, based on end use, holds the largest share as they serve as primary treatment centers offering comprehensive cancer care. Homecare is the fastest-growing segment due to the rising preference for at-home treatment options and advancements in drug delivery methods.
North America dominates the soft tissue sarcoma treatment market share due to high healthcare expenditure, advanced treatment availability, and strong regulatory support. Asia Pacific is the fastest-growing market, driven by improving healthcare infrastructure, rising awareness, and increasing adoption of advanced therapies.
A few notable market players are Amgen Inc.; AstraZeneca plc; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; and Sanofi.
Polaris Market Research has segmented the soft tissue sarcoma treatment market report on the basis of treatment, indication, distribution channel, end use, and region:
By Treatment Outlook (Revenue - USD Million, 2020-2034)
Chemotherapy
Targeted Therapy
Anti-angiogenesis Drugs
Radiation Therapy
By Indication Outlook (Revenue - USD Million, 2020-2034)
Regional
Local
Metastatic Sarcoma
By Distribution Channel Outlook (Revenue - USD Million, 2020-2034)
Online Pharmacy
Retail Pharmacy
Others
By End Use Outlook (Revenue - USD Million, 2020-2034)
Hospitals
Homecare
Others
By Regional Outlook (Revenue - USD Million, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Soft Tissue Sarcoma Treatment Market Insights
- 4.1. Soft Tissue Sarcoma Treatment Market - Market Snapshot
- 4.2. Soft Tissue Sarcoma Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Advancements in Targeted Therapies
- 4.2.1.2. Increasing Healthcare Expenditure
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Limited research funding
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Soft Tissue Sarcoma Treatment Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Soft Tissue Sarcoma Treatment Market, by Treatment
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 5.3. Chemotherapy
- 5.3.1. Global Soft Tissue Sarcoma Treatment Market, by Chemotherapy, by Region, 2020-2034 (USD Million)
- 5.4. Targeted Therapy
- 5.4.1. Global Soft Tissue Sarcoma Treatment Market, by Targeted Therapy, by Region, 2020-2034 (USD Million)
- 5.5. Anti-angiogenesis Drugs
- 5.5.1. Global Soft Tissue Sarcoma Treatment Market, by Anti-angiogenesis Drugs, by Region, 2020-2034 (USD Million)
- 5.6. Radiation Therapy
- 5.6.1. Global Soft Tissue Sarcoma Treatment Market, by Radiation Therapy, by Region, 2020-2034 (USD Million)
6. Global Soft Tissue Sarcoma Treatment Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 6.3. Regional
- 6.3.1. Global Soft Tissue Sarcoma Treatment Market, by Regional, by Region, 2020-2034 (USD Million)
- 6.4. Local
- 6.4.1. Global Soft Tissue Sarcoma Treatment Market, by Local, by Region, 2020-2034 (USD Million)
- 6.5. Metastatic Sarcoma
- 6.5.1. Global Soft Tissue Sarcoma Treatment Market, by Metastatic Sarcoma, by Region, 2020-2034 (USD Million)
7. Global Soft Tissue Sarcoma Treatment Market, by End-Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 7.3. Hospitals
- 7.3.1. Global Soft Tissue Sarcoma Treatment Market, by Hospitals, by Region, 2020-2034 (USD Million)
- 7.4. Homecare
- 7.4.1. Global Soft Tissue Sarcoma Treatment Market, by Homecare, by Region, 2020-2034 (USD Million)
- 7.5. Others
- 7.5.1. Global Soft Tissue Sarcoma Treatment Market, by Others, by Region, 2020-2034 (USD Million)
8. Global Soft Tissue Sarcoma Treatment Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3. Online Pharmacy
- 8.3.1. Global Soft Tissue Sarcoma Treatment Market, by Online Pharmacy, by Region, 2020-2034 (USD Million)
- 8.4. Retail Pharmacy
- 8.4.1. Global Soft Tissue Sarcoma Treatment Market, by Retail Pharmacy, by Region, 2020-2034 (USD Million)
- 8.5. Others
- 8.5.1. Global Soft Tissue Sarcoma Treatment Market, by Others, by Region, 2020-2034 (USD Million)
9. Global Soft Tissue Sarcoma Treatment Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Soft Tissue Sarcoma Treatment Market Assessment, By Geography, 2020-2034 (USD Million)
- 9.3. Soft Tissue Sarcoma Treatment Market - North America
- 9.3.1. North America: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.3.2. North America: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.3.3. North America: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.3.4. North America: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.3.5. Soft Tissue Sarcoma Treatment Market - US
- 9.3.5.1. US: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.3.5.2. US: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.3.5.3. US: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.3.5.4. US: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.3.6. Soft Tissue Sarcoma Treatment Market - Canada
- 9.3.6.1. Canada: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.3.6.2. Canada: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.3.6.3. Canada: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.3.6.4. Canada: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4. Soft Tissue Sarcoma Treatment Market - Europe
- 9.4.1. Europe: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.2. Europe: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.3. Europe: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.4. Europe: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.5. Soft Tissue Sarcoma Treatment Market - UK
- 9.4.5.1. UK: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.5.2. UK: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.5.3. UK: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.5.4. UK: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.6. Soft Tissue Sarcoma Treatment Market - France
- 9.4.6.1. France: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.6.2. France: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.6.3. France: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.6.4. France: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.7. Soft Tissue Sarcoma Treatment Market - Germany
- 9.4.7.1. Germany: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.7.2. Germany: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.7.3. Germany: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.7.4. Germany: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.8. Soft Tissue Sarcoma Treatment Market - Italy
- 9.4.8.1. Italy: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.8.2. Italy: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.8.3. Italy: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.8.4. Italy: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.9. Soft Tissue Sarcoma Treatment Market - Spain
- 9.4.9.1. Spain: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.9.2. Spain: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.9.3. Spain: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.9.4. Spain: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.10. Soft Tissue Sarcoma Treatment Market - Netherlands
- 9.4.10.1. Netherlands: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.10.2. Netherlands: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.10.3. Netherlands: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.10.4. Netherlands: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.11. Soft Tissue Sarcoma Treatment Market - Russia
- 9.4.11.1. Russia: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.11.2. Russia: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.11.3. Russia: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.11.4. Russia: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.4.12. Soft Tissue Sarcoma Treatment Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.4.12.2. Rest of Europe: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.4.12.3. Rest of Europe: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.4.12.4. Rest of Europe: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5. Soft Tissue Sarcoma Treatment Market - Asia Pacific
- 9.5.1. Asia Pacific: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.2. Asia Pacific: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.3. Asia Pacific: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.4. Asia Pacific: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.5. Soft Tissue Sarcoma Treatment Market - China
- 9.5.5.1. China: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.5.2. China: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.5.3. China: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.5.4. China: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.6. Soft Tissue Sarcoma Treatment Market - India
- 9.5.6.1. India: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.6.2. India: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.6.3. India: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.6.4. India: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.7. Soft Tissue Sarcoma Treatment Market - Malaysia
- 9.5.7.1. Malaysia: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.7.2. Malaysia: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.7.3. Malaysia: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.7.4. Malaysia: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.8. Soft Tissue Sarcoma Treatment Market - Japan
- 9.5.8.1. Japan: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.8.2. Japan: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.8.3. Japan: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.8.4. Japan: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.9. Soft Tissue Sarcoma Treatment Market - Indonesia
- 9.5.9.1. Indonesia: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.9.2. Indonesia: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.9.3. Indonesia: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.9.4. Indonesia: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.10. Soft Tissue Sarcoma Treatment Market - South Korea
- 9.5.10.1. South Korea: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.10.2. South Korea: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.10.3. South Korea: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.10.4. South Korea: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.11. Soft Tissue Sarcoma Treatment Market - Australia
- 9.5.11.1. Australia: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.11.2. Australia: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.11.3. Australia: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.11.4. Australia: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.5.12. Soft Tissue Sarcoma Treatment Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.5.12.2. Rest of Asia Pacific: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.5.12.3. Rest of Asia Pacific: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.5.12.4. Rest of Asia Pacific: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6. Soft Tissue Sarcoma Treatment Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.6.2. Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.6.3. Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.6.4. Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.5. Soft Tissue Sarcoma Treatment Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.6.5.2. Saudi Arabia: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.6.5.3. Saudi Arabia: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.6.5.4. Saudi Arabia: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.6. Soft Tissue Sarcoma Treatment Market - UAE
- 9.6.6.1. UAE: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.6.6.2. UAE: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.6.6.3. UAE: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.6.6.4. UAE: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.7. Soft Tissue Sarcoma Treatment Market - Israel
- 9.6.7.1. Israel: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.6.7.2. Israel: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.6.7.3. Israel: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.6.7.4. Israel: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.8. Soft Tissue Sarcoma Treatment Market - South Africa
- 9.6.8.1. South Africa: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.6.8.2. South Africa: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.6.8.3. South Africa: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.6.8.4. South Africa: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.6.9. Soft Tissue Sarcoma Treatment Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.6.9.2. Rest of Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.6.9.3. Rest of Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.6.9.4. Rest of Middle East & Africa: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7. Soft Tissue Sarcoma Treatment Market - Latin America
- 9.7.1. Latin America: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.7.2. Latin America: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.7.3. Latin America: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.7.4. Latin America: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.5. Soft Tissue Sarcoma Treatment Market - Mexico
- 9.7.5.1. Mexico: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.7.5.2. Mexico: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.7.5.3. Mexico: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.7.5.4. Mexico: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.6. Soft Tissue Sarcoma Treatment Market - Brazil
- 9.7.6.1. Brazil: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.7.6.2. Brazil: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.7.6.3. Brazil: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.7.6.4. Brazil: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.7. Soft Tissue Sarcoma Treatment Market - Argentina
- 9.7.7.1. Argentina: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.7.7.2. Argentina: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.7.7.3. Argentina: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.7.7.4. Argentina: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 9.7.8. Soft Tissue Sarcoma Treatment Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Soft Tissue Sarcoma Treatment Market, by Treatment, 2020-2034 (USD Million)
- 9.7.8.2. Rest of Latin America: Soft Tissue Sarcoma Treatment Market, by Indication, 2020-2034 (USD Million)
- 9.7.8.3. Rest of Latin America: Soft Tissue Sarcoma Treatment Market, by End-Use, 2020-2034 (USD Million)
- 9.7.8.4. Rest of Latin America: Soft Tissue Sarcoma Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Amgen Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. AstraZeneca plc
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Bayer AG
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Bristol-Myers Squibb Company
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Celgene Corporation
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Eli Lilly and Company
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. F. Hoffmann-La Roche AG
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. GlaxoSmithKline plc
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Johnson & Johnson Services, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Merck & Co., Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
